Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00469300 · ClinicalTrials.gov registry record · Phase 2
Iontophoretic Application of Acyclovir Gel to Treat Cold Sores
A Phase 2 study, sponsored by Transport Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 810
- Enrollment target
NCT00469300 is a Phase 2 study that has completed, run by Transport Pharmaceuticals. The registered enrollment target is 810 participants.
The verdict
NCT00469300, a Phase 2 study, has completed, sponsored by Transport Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 810 participants
- Enrollment target
Study Summary
Currently approved drugs for the treatment of herpes labialis (cold sores) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the sites where the herpes virus is replicating. Iontophoresis uses electric current to enhance delivery of drugs through the skin. This trial is testing a new iontophoretic device with a new acyclovir gel to treat cold sores.
Interventions
- DRUG Iontophoretic delivery of acyclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 810 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00469300
The ClinicalTrials.gov registry entry for NCT00469300 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 810 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Transport Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Iontophoretic delivery of acyclovir is the first listed.
NCT00469300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00469300 about?
NCT00469300 is a clinical study titled "Iontophoretic Application of Acyclovir Gel to Treat Cold Sores". Currently approved drugs for the treatment of herpes labialis (cold sores) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the sites where the herpes virus is replicating. Iontophoresis uses electric current to enhance delivery of drugs through the ski...
What is the current status of trial NCT00469300?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 810 participants. The study started on 2007-04. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00469300?
The interventions under investigation include: Iontophoretic delivery of acyclovir (DRUG).
Who is sponsoring clinical trial NCT00469300?
This trial is sponsored by Transport Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.